Thaís  Oliveira

Mrs. Thaís Oliveira


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
ODOdir Dellagostin
Odir Dellagostin
AGAndre Grassmann
Andre Grassmann
CRCaroline Rizzi
Caroline Rizzi
RSRodrigo A. Schuch
Rodrigo A. Schuch
SJSérgio Jorge
Sérgio Jorge
DHDaiane Drawanz Hartwig
Daiane Drawanz Hartwig
Leptospirosis is a major public health problem with an incidence of over one million human cases each year. It is a globally distributed, zoonotic disease and is associated with significant economic losses in farm animals. Leptospirosis is caused by pathogenic Leptospira spp. that can infect a wide range of domestic and wild animals. Given the inability to control the cycle of transmission among animals and humans, there is an urgent demand for a new vaccine. Inactivated whole-cell vaccines (bacterins) are routinely used in livestock and domestic animals, however, protection is serovar-restricted and short-term only. To overcome these limitations, efforts have focused on the development of recombinant vaccines, with partial success. Reverse vaccinology (RV) has been successfully applied to many infectious diseases. A growing number of leptospiral genome sequences are now available in public databases, providing an opportunity to search for prospective vaccine antigens using RV. Several promising leptospiral antigens were identified using this approach, although only a few have been characterized and evaluated in animal models. In this review, we summarize the use of RV for leptospirosis and discuss the need for potential improvements for the successful development of a new vaccine towards reducing the burden of human and animal leptospirosis.

6 December 2010 in Microbial Cell Factories
Verified
Journal Article
Open access
PDF file
DHDaiane Drawanz Hartwig
Daiane Drawanz Hartwig
TThaís Oliveira
Thaís Oliveira
FSFabiana Seixas
Fabiana Seixas
KFKarine M Forster
Karine M Forster
CRCaroline Rizzi
Caroline Rizzi
ODOdir Dellagostin
Odir Dellagostin
Background: Leptospirosis, a zoonosis caused by Leptospira spp., is recognized as an emergent infectious disease. Due to the lack of adequate diagnostic tools, vaccines are an attractive intervention strategy. Recombinant proteins produced in Escherichia coli have demonstrated promising results, albeit with variable efficacy. Pichia pastoris is an alternative host with several advantages for the production of recombinant proteins. Results: The vaccine candidates LigANI and LipL32 were cloned and expressed in P. pastoris as secreted proteins. Large-scale expression resulted in a yield of 276 mg/L for LigANI and 285 mg/L for LipL32. The recombinant proteins were glycosylated and were recognized by antibodies present in the sera of patients with severe leptospirosis. Conclusions: The expression of LigANI and LipL32 in P. pastoris resulted in a significant increase in yield compared to expression in E. coli. In addition, the proteins were secreted, allowing for easy purification, and retained the antigenic characteristics of the native proteins, demonstrating their potential application as subunit vaccine candidates.

31 May 2023 in Pathogens
Verified
Journal Article
Open access
PDF file
NONatasha de Oliveira
Natasha de Oliveira
FSFrancisco Denis Souza Santos
Francisco Denis Souza Santos
VSVitória Adrielly Catschor dos Santos
Vitória Adrielly Catschor dos Santos
MMMara Maia
Mara Maia
TThaís Oliveira
Thaís Oliveira
ODOdir Dellagostin
Odir Dellagostin
The first leptospiral recombinant vaccine was developed in the late 1990s. Since then, progress in the fields of reverse vaccinology (RV) and structural vaccinology (SV) has significantly improved the identification of novel surface-exposed and conserved vaccine targets. However, developing recombinant vaccines for leptospirosis faces various challenges, including selecting the ideal expression platform or delivery system, assessing immunogenicity, selecting adjuvants, establishing vaccine formulation, demonstrating protective efficacy against lethal disease in homologous challenge, achieving full renal clearance using experimental models, and reproducibility of protective efficacy against heterologous challenge. In this review, we highlight the role of the expression/delivery system employed in studies based on the well-known LipL32 and leptospiral immunoglobulin-like (Lig) proteins, as well as the choice of adjuvants, as key factors to achieving the best vaccine performance in terms of protective efficacy against lethal infection and induction of sterile immunity.

18 October 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
DCDomitila Brzoskowski Chagas
Domitila Brzoskowski Chagas
FSFrancisco Denis Souza Santos
Francisco Denis Souza Santos
NONatasha de Oliveira
Natasha de Oliveira
TThaís Oliveira
Thaís Oliveira
ODOdir Dellagostin
Odir Dellagostin
Vaccination is essential in maintaining animal health, with a priority on safety and cost-effectiveness in veterinary vaccines. The development of recombinant live-attenuated Salmonella vaccines (RASVs) has enabled the construction of balanced lethal systems, ensuring the stability of plasmid vectors encoding protective antigens post-immunization. These vaccines are particularly suitable for production animals, providing long-term immunity against a range of bacterial, viral, and parasitic pathogens. This review summarizes the progress made in this field, with a focus on clinical trials demonstrating the efficacy and commercial potential of RASVs in veterinary medicine.

9 January 2026 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
LMLaura de V. Maiocchi
Laura de V. Maiocchi
NONatasha R. de Oliveira
Natasha R. de Oliveira
MMMara A. C. Maia
Mara A. C. Maia
APAna C. K. Pedra
Ana C. K. Pedra
TBTiffany T. Bunde
Tiffany T. Bunde
TThaís Oliveira
Thaís Oliveira

11 May 2026 in Molecular Biology Reports
Verified
Journal Article
Open access
PDF file
APAna C. K. Pedra
Ana C. K. Pedra
NONatasha R. de Oliveira
Natasha R. de Oliveira
MMMara A. C. Maia
Mara A. C. Maia
AMAndriele B. Madruga
Andriele B. Madruga
BSBeatriz C. M. Santos
Beatriz C. M. Santos
TThaís Oliveira
Thaís Oliveira
Cytokines are small glycosylated polypeptides that orchestrate immune responses and are widely produced in recombinant form for therapeutic and research purposes. This review highlights Komagataella phaffii as an efficient host for the heterologous expression of recombinant cytokines from human and other species. A systematic search of PubMed, Scopus, and Web of Science identified studies addressing upstream and downstream processes involved in cytokine expression. Molecular design strategies such as codon optimization, vector design, and signal peptide selection are discussed together with process parameters including temperature, inducer concentration, and bioreactor conditions, as well as recovery and purification of biologically active cytokines. Optimal production is often associated using multi-copy vectors driven by the AOX1 promoter, α-factor secretion signals, methanol induction (0.5–1.5% v/v), temperatures below 30 °C, and co-feeding strategies. Downstream purification commonly yields products exceeding 95% purity. Strategies such as PEGylation, albumin fusion, and antibody fusion are also described to improve cytokine stability and half-life. This review integrates and critically analyzes molecular and bioprocessing advances that establish K. phaffii as a powerful platform for recombinant cytokine production.